1422469-70-2

Upstream product

• 42288-26-6 (4-cyanophenyl)glycine 
• 212322-56-0 ethyl 3-{[{2-amino-1-(methylamino)phen-4-yl}carbonyl](pyridyn-2-yl)amino}propanoate 
• 110-15-6 succinic acid 
• 211915-84-3 3-[[[2-[[(4-cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propionic acid ethyl ester 

Downstream Products

• 1422435-39-9 ethyl 2-[[4-(aminoiminomethyl)phenylamino]methyl]-1-methyl-1H-benzimidazole-5-carboxylate hydrochloride 
• 1408238-36-7 ethyl 2-[[4-[(n-hexyloxycarbonyl)aminoiminomethyl]phenylamino]methyl]-1-methyl-1H-benzimidazole-5-carboxylate 
• 1354727-65-3 ethyl 3-[[2-[[ethoxy(imino)methylphenylamino]methyl]-1-methyl-1H-benzimidazole-5-carbonyl]pyridin-2-yl-amino]propionate hydrochloride 
• 1427571-33-2 C₂₁H₂₄N₄O₃*ClH 

Relevant academic research and scientific papers

Synthesis, characterization and suppression of impurities during optimization of dabigatran etexilate

The synthetic methods for two impurities of dabigatran etexilate are firstly described, and both of two impurities are characterized by NMR and MS spectral data. The suppression of impurities as well as the optimization process of dabigatran etexilate is also disclosed.